Legal & General Group Plc Sells 1,740,342 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Legal & General Group Plc lessened its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 34.9% in the fourth quarter, Holdings Channel reports. The firm owned 3,250,262 shares of the company’s stock after selling 1,740,342 shares during the period. Legal & General Group Plc’s holdings in Teva Pharmaceutical Industries were worth $71,636,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in TEVA. Captrust Financial Advisors grew its position in Teva Pharmaceutical Industries by 48.4% during the third quarter. Captrust Financial Advisors now owns 15,786 shares of the company’s stock valued at $284,000 after buying an additional 5,146 shares during the period. HighTower Advisors LLC increased its stake in shares of Teva Pharmaceutical Industries by 461.8% during the 3rd quarter. HighTower Advisors LLC now owns 148,605 shares of the company’s stock worth $2,675,000 after purchasing an additional 122,154 shares during the last quarter. Quantinno Capital Management LP raised its holdings in shares of Teva Pharmaceutical Industries by 34.5% in the 3rd quarter. Quantinno Capital Management LP now owns 36,145 shares of the company’s stock worth $651,000 after purchasing an additional 9,269 shares during the period. Stifel Financial Corp lifted its stake in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after purchasing an additional 23,283 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new position in Teva Pharmaceutical Industries during the third quarter valued at $453,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Bank of America dropped their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday, April 4th. Barclays lowered their price target on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $13.42 on Friday. The firm has a 50 day moving average of $15.79 and a 200-day moving average of $17.82. The firm has a market capitalization of $15.22 billion, a P/E ratio of -9.26, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.